Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 31, 2015
Pharmacy Choice - News - U.S. Pharmaceutical Industry - January 31, 2015

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

1/31/15 - "Methods and Use of Inducing Apoptosis in Cancer Cells" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors Narain, Niven Rajin; Persaud, Indushekhar; McCook, John Patrick, filed on February 10, 2014, was made available online on January 15, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This pate
1/31/15 - Actavis Launches U.S. Generic Specialty Injectable Portfolio
By a News Reporter-Staff News Editor at Marketing Weekly News Actavis plc, a leading global specialty pharmaceutical company, announced the launch of a leading portfolio of generic specialty injectable medications to be marketed to hospitals across the United States. Actavis also has an industry leading specialty injectable pipeline, with...
1/31/15 - Alimera Sciences' ILUVIEN Achieves Marketing Authorization in Finland and Luxembourg [Professional Services Close - Up]
Alimera Sciences reported that marketing authorization has been granted by the Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. ILUVIEN is now approved for...
1/31/15 - Arena Pharmaceuticals Assigned Patent for Modulators of Prostacyclin (PGI2) Receptor
ALEXANDRIA, Va., Jan. 31 Arena Pharmaceuticals, San Diego, has been assigned a patent developed by five co-inventors for "modulators of prostacyclin receptor useful for treatment of disorders related thereto." The co-inventors are Rena Hayashi, Hacienda Heights, California, Thuy-Anh Tran, San Diego, Brett Ullman, San Diego, Ning Zou, San Diego, a
1/31/15 - Cancer-fighting start-up Invenra lands $2 million [The Wisconsin State Journal]
Jan. 31 Invenra, a young Madison company looking to help develop a new class of drugs to fight cancer, has raised another $2 million from investors. Founded in 2012, most of Invenra's board of directors, including chief executive Roland Green, worked together as leaders of NimbleGen Systems, a Madison company purchased by global drug giant Roche
1/31/15 - Intercept Pharmaceuticals Soars 20%, Possible Short Squeeze; Vital Therapies Announces VTI-208 Phase 3 Clinical Trial Reaches Enrollment Target
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 30, 2015.{ nfg} Shares of Intercept Pharmaceuticals Inc. soared more than 20 percent Friday following a favorable FDA ruling on Thursday. Intercept Pharmaceuticals recently traded at $209.41, up 22.7 percent.=============================== Vita
1/31/15 - Pfizer Reports Fourth-Quarter and Full-Year 2014 Results; Supplies 2015 Financial Guidance [Professional Services Close - Up]
Pfizer reported financial results for fourth-quarter and full- year 2014.. The Innovative Products business is composed of two operating segments: the Global Innovative Pharmaceutical segment and the Global Vaccines, Oncology and Consumer Healthcare segment. As a result of the full disposition of Zoetis on June 24, 2013, the financial results of th
1/31/15 - Plaintiffs Level Allegations Against Maker of Prescription Drug Risperdal [Professional Services Close - Up]
Attorney Wendy R. Fleishman of the law firm Lieff Cabraser Heimann& Bernstein reported that four young men prescribed the antipsychotic medication Risperdal recently filed separate personal injury lawsuits alleging that Risperdal is a defective and dangerous prescription drug. According to a company release, the complaints were brought against...
1/31/15 - Prasco and Takeda Enter into Agreement to Market Authorized Generic of Colcrys colchicine, USP in the United States
By a News Reporter-Staff News Editor at Marketing Weekly News Prasco Laboratories, Takeda Pharmaceutical Company Limited, and Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. announced that Prasco and TPUSA have entered into a distribution and supply agreement for the rights to distribute Colchicine Tablets, USP, the Authoriz
1/31/15 - Researchers Submit Patent Application, "Methods of Treating Amyotrophic Lateral Sclerosis", for Approval
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week From Washington, D.C., NewsRx journalists report that a patent application by the inventor Gjorstrup, Per, filed on February 15, 2013, was made available online on January 15, 2015. The patent's assignee is Anida Pharma Inc.. News editors obtained the following quote from the
1/31/15 - Shire Says FDA Approves Vyvanse To Treat Binge Eating Disorder
SAINT HELIER- Shire plc said Friday that the U.S. Food and Drug Administration has approved Vyvanse Capsules, the first and only medication for the treatment of moderate to severe binge eating disorder in adults, shown to significantly reduce the mean number of binge days per week. Vyvanse is not indicated or recommended for weight loss or the trea
1/31/15 - St. Jude Medical Updates on FDA Approval of FlexAbility Ablation Catheter [Professional Services Close - Up]
St. Jude Medical reported U.S. Food and Drug Administration approval of the FlexAbility Ablation Catheter, a new ablation technology used by electrophysiologists for the treatment of cardiac arrhythmias. Andrea Natale, executive medical director at the Texas Cardiac Arrhythmia Institute. "As we developed the FlexAbility ablation catheter, we worke
1/31/15 - SynteractHCR to Present at International and Domestic Clinical Trials Conferences [Professional Services Close - Up]
SynteractHCR will participate in two biopharmaceutical and life science conferences in early February: the European CRO Federation's 2nd European Conference on Clinical Research in Paris, and the 7th Annual Outsourcing in Clinical Trials West Coast Conference in San Francisco. Martine Dehlinger-Kremer, is attending EUCROF's conference and chairing
1/31/15 - Teikoku Pharma USA Assigned Patent for Non-Aqueous Taxane Nanodispersion Formulations
ALEXANDRIA, Va., Jan. 31 Teikoku Pharma USA, San Jose, California, has been assigned a patent developed by Kiichiro Nabeta, Tokyo, for methods "for using non-aqueous taxane nanodispersion formulations." The patent was filed on Sept. 30, 2013. Written by Aile Dayandante; edited by Vessie Ann Abalos.
1/31/15 - Testosterone Lawyers at Bernstein Liebhard LLP Comment on Study Questioning Association Between Testosterone Therapy and Serious Heart Problems
The testosterone lawyers at Bernstein Liebhard LLP note the publication of a new study that purports to question the association between prescription testosterone therapy and serious cardiovascular problems. "These findings come just months after a panel of FDA advisors recommended that the manufacturers of testosterone therapies undertake large..
1/31/15 - Trimel Files New Drug Submission for NATESTO with Health Canada [Professional Services Close - Up]
Trimel Pharmaceuticals has filed a New Drug Submission with Health Canada for NATESTO nasal gel for replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone. "The filing of NATESTO with Health Canada represents another significant milestone for Trimel and the many patients this therapy aims to ad
1/31/15 - U.S. Patents Awarded to Inventors in Nevada (Jan. 31)
ALEXANDRIA, Va., Jan. 31 The following federal patents were awarded to inventors in Nevada. ALEXANDRIA, Va., Jan. 31 Arena Pharmaceuticals, San Diego, has been assigned a patent developed by five co-inventors for "modulators of prostacyclin receptor useful for treatment of disorders related thereto." The co-inventors are Rena Hayashi, Hacienda
1/31/15 - United States : U.S. FDA Approves IMBRUVICA(ibrutinib) for the Treatment of Waldenstrom's Macroglobulinemia: First FDA-Approved Therapy for This... [TendersInfo (India)]
Janssen Biotech, Inc. today announced that the U.S. Food and Drug Administration has approved IMBRUVICA capsules as the first therapy indicated specifically for patients with Waldenstrm s macroglobulinemia, a rare, indolent type of B-cell lymphoma. IMBRUVICA was granted Breakthrough Therapy Designation for WM by the FDA and is being jointly devel
1/31/15 - Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder
Shire plc announced today that the U.S. Food and Drug Administration approved Vyvanse Capsules, the first and only medication for the treatment of moderate to severe binge eating disorder in adults, shown to significantly reduce the mean number of binge days per week. "Binge eating disorder is the most common adult eating disorder in the Unit
1/31/15 - Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER
Zogenix, Inc., a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders, today announced that the U.S. Food and Drug Administration has approved a new formulation of Zohydro ER Extended-Release Capsules, CII, with BeadTek?. Concurrently, Zogenix has ongoing Human Abuse Liability s
1/30/15 - Alimera Sciences' ILUVIEN Achieves Marketing Authorization in Finland and Luxembourg [Manufacturing Close - Up]
Alimera Sciences reported that marketing authorization has been granted by the Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. ILUVIEN is now approved for...
1/30/15 - AMITIZA(R) (lubiprostone) Mutual Recognition Procedure Closes With Recommendation for Approval in European Countries
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced the successful completion of the European Mutual Recognition Procedure for AMITIZA for the treatment of chronic idiopathic constipation in select European countries, resulting in a recommendation for marketing authorization. Based on the approval in the United..
1/30/15 - Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Cedar Pollinosis
HERSHEY, Pa., Rockville, Md. and TOKYO, Jan. 29, 2015/ PRNewswire/ Immunomic Therapeutics, Inc., a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. today announced they have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics'
1/30/15 - AstraZeneca's genetic scissors to refine drugs
UK DRUG giant AstraZeneca said yesterday it has struck four research agreements in the hot area of genome editing as it bets on a new "genetic scissors" technology to deliver better and more precise drugs for a range of diseases. The deals will allow AstraZeneca to use its so-called CRISPR technology, which stands for clustered regularly interspace
1/30/15 - Calithera Biosciences Appoints Keith Orford, M.D., Ph.D. to Vice President of Clinical Development
Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today the appointment of Dr. At Calithera, Dr. Orford will be responsible for clinical development of CB-839, it
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part I: Cardiovascular Disorders
This lesson is supported by:
RxSchool
Workplace Safety & Joint Commission Standards for Pharmacy Professionals
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415